Related Experiment Video
Updated: Jul 9, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Exploiting signal transduction pathways in acute myelogenous leukemia
Alexander E Perl1, Martin Carroll
1Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, USA. Alexander.Perl@uphs.upenn.edu
Abstract:
Traditional cytotoxic chemotherapy is effective at temporizing AML in the majority of patients but cures a small minority. Thus, enrollment in clinical trials remains a recommended approach for nearly all patients. While signal transduction inhibition is a promising area to advance AML therapy, no agent as monotherapy has demonstrated obvious clinical benefit over traditional cytotoxic chemotherapy. Tipifarnib is perhaps an exception as it is the only signal transduction inhibitor in AML that reproducibly shows clinical benefit using traditional chemotherapy response criteria. Due to toxicity and low response rates, however, the potential advantages of tipifarnib over either traditional cytotoxic chemotherapy or best supportive care alone await confirmation from phase III studies. Available data suggest that combining signal transduction inhibitors with chemotherapy will improve response rates. Clinical trials to test this hypothesis are ongoing using various agents directed against targets such as FLT3, ras/raf/MAPK, mTOR, KIT, and VEGF, but the optimal approach is yet to be defined. Similarly unclear is the benefit of a potent specific kinase inhibitor versus a broad inhibitor of multiple kinases that could prove relevant to leukemia biology. In general, the incomplete understanding of many signal transduction inhibitors' true mechanism of action limits our ability to identify pretreatment predictors of response. To this end, the extensive measures applied to correlate the biologic activity of FLT3 inhibitors with clinical responses are noteworthy and provide useful lessons for clinical trial design and drug development both in leukemia and other cancers.
Insights
Signal transduction inhibitors show promise for treating acute myeloid leukemia (AML), with tipifarnib demonstrating clinical benefit. Combining these inhibitors with chemotherapy may improve response rates in AML treatment.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Acute myeloid leukemia (AML) treatment relies on cytotoxic chemotherapy, offering temporary control but limited cures.
- Signal transduction inhibitors represent a promising therapeutic avenue for AML, though monotherapy benefits over traditional chemotherapy are not yet established.
- Tipifarnib is a notable exception, showing reproducible clinical benefit in AML when assessed by standard chemotherapy response criteria.
Purpose of the Study:
- To evaluate the potential of signal transduction inhibitors in AML therapy.
- To explore the efficacy of tipifarnib as a monotherapy and in combination treatments.
- To discuss the ongoing research and challenges in optimizing AML treatment strategies using targeted therapies.
Main Methods:
- Review of existing clinical data and response criteria for AML treatments.
- Analysis of signal transduction inhibitors, including tipifarnib, FLT3 inhibitors, and others targeting pathways like ras/raf/MAPK, mTOR, KIT, and VEGF.
- Examination of ongoing clinical trials investigating combination therapies and novel drug development.
Main Results:
- Tipifarnib demonstrates clinical benefit in AML, though its advantages over chemotherapy require Phase III confirmation due to toxicity and response rates.
- Combining signal transduction inhibitors with chemotherapy is hypothesized to improve response rates.
- Clinical trials are actively investigating various targeted agents and combinations, but optimal approaches remain undefined.
Conclusions:
- Signal transduction inhibitors hold significant potential for advancing AML therapy, particularly in combination regimens.
- Further research, including Phase III studies, is crucial to confirm the benefits of agents like tipifarnib and to define optimal treatment strategies.
- Understanding the precise mechanisms of action and identifying predictive biomarkers are essential for effective clinical trial design and drug development in AML.
Related Concept Videos
01:22Amplifying Signals via Enzymatic Cascade
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:23Abnormal Proliferation
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:26Signal Transduction: Overview
Typically, signal transduction involves three...